Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TC vs TAC in HER2-Negative Early Stage Breast Cancer
NCT00493870Phase 3Completed
- Sponsor
- US Oncology Network
- Start
- May 2007
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of docetaxel in breast cancer (2 arms), sponsored by US Oncology Network. Primary endpoints: Invasive Disease-free Survival at 3 years and Invasive Disease-free Survival (Per-protocol) at 3 years. Started May 2007; status: completed.
02
Drugs
docetaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00493870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00493870.